Canadian robotics company Realbotix Corp. has agreed to transfer its commercial humanoid robotics business to Onconetix, Inc., a NASDAQ-listed firm, in an all-stock transaction. The deal effectively separates Realbotix’s business activities, placing its professional robotics operations in a U.S.-listed company while retaining its adult-focused consumer division.
Under the agreement, signed on February 11, 2026, Onconetix will acquire 100 percent of Realbotix, LLC, Realbotix’s U.S.-based subsidiary responsible for developing humanoid robots for commercial applications. These include customer service, healthcare, hospitality, education, and entertainment.
In return, Realbotix will receive newly issued shares in Onconetix, giving it between 75 and 90 percent of the combined company’s fully diluted share capital, depending on Onconetix’s cash position at closing. Realbotix will also gain the right to appoint four of the five board members, securing operational control of the new structure.
Separation of Business Activities
With the transaction, Realbotix is formally separating its two main business lines. The commercial robotics unit will operate within Onconetix, which is expected to rebrand under the Realbotix name or a similar identity. The Canadian parent company will continue to operate Abyss Creations, which focuses on adult companionship products and related AI technologies.
According to Realbotix, the separation is intended to allow both divisions to develop independently and to provide the robotics business with greater access to U.S. capital markets. By moving the humanoid robotics unit into a NASDAQ-listed company, management aims to increase visibility among institutional investors.
Reverse Merger Structure
Rather than a traditional cash sale, the transaction resembles a reverse merger. Onconetix, previously focused on biotechnology and diagnostics, will shift its strategic focus toward humanoid robotics after the acquisition. Realbotix shareholders will retain majority ownership through their equity stake, while the robotics business gains a U.S. public listing.
The assets transferred to Onconetix include engineering teams, AI software developers, patents, and intellectual property related to humanoid robotics. Realbotix has stated that Realbotix LLC carried a book value of approximately $1.8 million, representing about 18 percent of its balance sheet.
Market Reaction and Timing
Following the announcement, Onconetix’s share price declined, reflecting investor concerns about dilution and the company’s change in strategic direction. Analysts have noted that the move represents a significant pivot away from its previous life sciences focus.
The transaction remains subject to regulatory approvals, including consent from the TSX Venture Exchange and Onconetix shareholders. Realbotix expects the deal to close before the end of the third quarter of 2026.
